ClinicalTrials.gg
CompletedNCT02199574Updated Mar 8, 2021Results posted

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

A Phase 4 interventional study of EXPAREL in Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-08.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.

Enrollment
30th of 36
12 · median 60
Started
2014
with 10 others
Phase 4
22 of 36
2 open now
Registered
8th of 36
by date
Lead sponsor
7 of 36
Pacira Pharmaceuticals, Inc

Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 30th largest by enrollment, is one of 11 that started in 2014, is one of 22 in phase 4, and was the 8th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Liposomal Bupivacaine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the pharmacokinetic (PK) profile of a single dose of EXPAREL (133 mg/10 mL) administered intraoperatively per normal infiltration for prolonged analgesia in 12 adult subjects undergoing tonsillectomy with or without removal of the adenoids.

Read the detailed description

Blood samples for bupivacaine PK analysis will be obtained from subjects at baseline (within 30 minutes prior to EXPAREL infiltration), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 36, 48, and 72 hours after the beginning of EXPAREL infiltration, and on Day 7.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ≥18 years of age at the Screening Visit.
  • Subjects undergoing tonsillectomy with or without removal of the adenoids.
  • Able and willing to comply with all study visits and procedures.
  • Willing and capable of providing written .

Exclusion criteria

Exclusion Criteria:

  • History of or idiosyncratic reaction to amide-type local anesthetics.
  • Received any drug within 30 days prior to EXPAREL administration, and/or has planned administration of another investigational product or procedure while participating in this study.
  • Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after EXPAREL administration. Female subjects must be surgically sterile, at least 2 years , or using an acceptable method of . If of , must have a documented negative pregnancy test within 24 hours before EXPAREL administration.
  • Subjects with significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to EXPAREL and/or procedures, or cause inability to comply with the study requirements.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    EXPAREL

    Single administration of EXPAREL 133 mg (10 mL).

    Drug: EXPAREL

Interventions

  • 133 mg EXPAREL in 10 mL.

    Also known as: bupivacaine liposome injectable suspension

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: From time of study drug administration through Day 7 postdose

  2. Time to Maximum Plasma Concentration (Tmax)

    Time frame: From time of study drug administration through Day 7 postdose

  3. Area Under the Plasma Concentration Versus Time Curve (AUC(0-t))

    Time frame: From time of study drug administration through Day 7 postdose

  4. Apparent Terminal Elimination Half-life

    Time frame: From time of study drug administration through Day 7 postdose

  5. Area Under the Plasma Concentration Versus Time Curve (AUC(0-infinity))

    Time frame: From time of study drug administration through Day 7 postdose

  6. The Apparent Terminal Elimination Rate Constant (λz)

    Time frame: From time of study drug administration through Day 7 postdose

07

Results

Posted Jun 29, 2016

Participant flow

Participant flow — Overall Study
MilestoneEXPAREL
Started12
Completed12
Not completed0

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax)
Time frame:
From time of study drug administration through Day 7 postdose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLEXPAREL
Maximum Plasma Concentration (Cmax)254 ± 82.6
PrimaryTime to Maximum Plasma Concentration (Tmax)
Time frame:
From time of study drug administration through Day 7 postdose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax)
hoursEXPAREL
Time to Maximum Plasma Concentration (Tmax)0.50 (0.22 to 35.7)
PrimaryArea Under the Plasma Concentration Versus Time Curve (AUC(0-t))
Time frame:
From time of study drug administration through Day 7 postdose
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUC(0-t))
hours*ng/mLEXPAREL
Area Under the Plasma Concentration Versus Time Curve (AUC(0-t))7150 ± 3189
PrimaryApparent Terminal Elimination Half-life
Time frame:
From time of study drug administration through Day 7 postdose
Reported as:
Mean · hours
Apparent Terminal Elimination Half-life
hoursEXPAREL
Apparent Terminal Elimination Half-life9.34 ± 2.31
PrimaryArea Under the Plasma Concentration Versus Time Curve (AUC(0-infinity))
Time frame:
From time of study drug administration through Day 7 postdose
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUC(0-infinity))
hours*ng/mLEXPAREL
Area Under the Plasma Concentration Versus Time Curve (AUC(0-infinity))6379 ± 2825
PrimaryThe Apparent Terminal Elimination Rate Constant (λz)
Time frame:
From time of study drug administration through Day 7 postdose
Reported as:
Mean · 1/hours
The Apparent Terminal Elimination Rate Constant (λz)
1/hoursEXPAREL
The Apparent Terminal Elimination Rate Constant (λz)0.07779 ± 0.02222

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL—0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventEXPAREL
pyrexiaGeneral disorders1/12
rashSkin and subcutaneous tissue disorders1/12

Baseline characteristics

11 participants received 133 mg/10 mL EXPAREL following protocol amendment subsequent to 1 participant receiving 266 mg/20 mL EXPAREL according to the original protocol.

Age, Categorical
Age, Categorical(Participants)EXPAREL
<=18 years1
Between 18 and 65 years11
>=65 years0
Age, Continuous
Age, Continuous(years)EXPAREL
Mean35.6 ± 13.30
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL
Female6
Male6
Region of Enrollment
Region of Enrollment(participants)EXPAREL
United States12
08

Study locations

2 sites
  • Memorial Hermann - Memorial City Medical Center
    Houston, Texas 77024, United States
  • Memorial Village Surgery Center
    Houston, Texas 77024, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Apr 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2014
First posted
Jul 24, 2014
Start
Aug 2014
Primary completionActual
Apr 2015
CompletionActual
Jun 2015
Results first posted
Jun 29, 2016
Last update
Mar 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02199574
Responsible party
Sponsor
First posted
Jul 24, 2014
Start date
Aug 2014
Primary completion
Apr 2015
Completion
Jun 2015
Results posted
Jun 29, 2016
Last update
Mar 8, 2021

Study contacts

Harold Minkowitz, MD
principal investigator · Herman Memorial Hospital, Houston TX

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion